Drug Trial Radar · NCT05041309
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,500
Planned (sponsor's estimate)
Start
Dec 15, 2021
Primary completion
Dec 2040
Study completion Dec 2040
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Sep 13, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, anitocabtagene autoleucel, INT2104, KITE-512, ACLX-001, and ACLX002 in participants of Kite-sponsored interventional studies. The primary objectives of this study are to: * Evaluate the incidence and severity of related SAEs, late-onset targeted AEs/SAEs suspected to be possibly related to gene-modified cell therapy, including neurologic disorders, new autoimmune disorders (which are distinct from the study-treated disease), hematologic disorders, serious infections, as well as any new malignancies (regardless of causality) * Evaluate the growth, development, and sexual maturity of pediatric and adolescent participants treated with gene-modified cell therapy.
Conditions
- Solid and Hematological Malignancies
- Autoimmune Diseases
Interventions
Axicabtagene CiloleucelBiological
No investigational product will be administered
Brexucabtagene AutoleucelBiological
No investigational product will be administered
Anitocabtagene autleucelBiological
No investigational product will be administered
KITE-753Biological
No investigational product will be administered
KITE-197Biological
No investigational product will be administered
KITE-363Biological
No investigational product will be administered
INT2104Biological
No investigational product will be administered
KITE-512Biological
No investigational product will be administered
SPRX001Biological
No investigational product will be administered
SPRX002Biological
No investigational product will be administered
ARC-T CellsBiological
No investigational product will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)Time frame: Up to 15 years
- Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)Time frame: Up to 15 years
- Percentage of Participants With New MalignanciesTime frame: Up to 15 years
- Percentage of Participants Experiencing Related SAEsTime frame: Up to 15 years
- Height of Pediatric and Adolescent ParticipantsTime frame: Up to 15 years
- Weight of Pediatric and Adolescent ParticipantsTime frame: Up to 15 years
- Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale ScoreTime frame: Up to 15 years
Locations
91 sites in 14 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
City of Hope
Duarte, California
UC San Diego Moores Cancer Center
La Jolla, California
Children's Hospital Los Angeles
Los Angeles, California
University of California Los Angeles
Los Angeles, California
Children's Hospital of Orange County
Orange, California
Stanford University
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
University of California, San Francisco Medical Center
San Francisco, California
Colorado Blood Cancer Institute
Denver, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Sylvester Comprehensive Cancer Centre
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Ann& Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Chicago Medical Center Clinical Laboratories
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
University of Iowa
Iowa City, Iowa
The University of Kansas Cancer Center Westwood
Westwood, Kansas
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Center Institute
Detroit, Michigan
Washington University
St Louis, Missouri
University of Nebraska
Omaha, Nebraska
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Ichann School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
University of Rochester Medical Center
Rochester, New York
Mayo Clinic
Rochester, New York
Montefiore Medical Center
The Bronx, New York
DUHS-Duke Blood Cancer Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
James Cancer Hospital and Solove Research Institute
Columbus, Ohio
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Prisma Health Cancer Institute
Greenville, South Carolina
Tennessee Oncology, PLLC
Nashville, Tennessee
Vanderbilt University
Nashville, Tennessee
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.